BioCryst adding to influenza stockpiles: Ticker Trax Update
In a conference call this morning, BioCryst Pharmaceuticals said its influenza treatment, administered intravenously, is in the midst of a U.S. government review for emergency use.
Latest Ticker Trax Report Reveals Fair Value of BioCryst Pharmaceuticals Inc. (BCRX)
Today Stockhouse.com announced the release of its newest issue of Ticker Trax, an investment report written by Thom Calandra. This report reveals a special focus on BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX), a developer of the anti-viral peramivir, which was identified in December 2008 as a ‘Top Portfolio Prospect’ for subscribers in the life sciences component of the Ticker Trax portfolio. The recent influenza outbreaks saw shares of BioCryst gain nearly 140% this week alone, leaving many wondering what’s next for this dynamic stock.
